 Connection
Paul Maroni to Prostatic Neoplasms
This is a "connection" page, showing publications Paul Maroni has written about Prostatic Neoplasms.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
4.292 |
|
|
|
-
Makedon A, Maroni P. Median Lobe Urethral Embolus After Focal Ablation of Gleason 7 Prostate Cancer. Oncology (Williston Park). 2021 07 13; 35(7):422-424.
Score: 0.480
-
Maroni PD. Is radical prostatectomy appropriate for very-high-risk prostate cancer patients? Yes. Oncology (Williston Park). 2015 May; 29(5):348, 388.
Score: 0.312
-
Maroni P, Crawford ED. Assessment of men before androgen deprivation therapy. J Urol. 2011 Aug; 186(2):371-2.
Score: 0.239
-
Maroni PD, Crawford ED. The benefits of early androgen blockade. Best Pract Res Clin Endocrinol Metab. 2008 Apr; 22(2):317-29.
Score: 0.191
-
Maroni PD, Crawford ED. Screening for prostate cancer in 2006: PSA in the 21st century. N C Med J. 2006 Mar-Apr; 67(2):136-9.
Score: 0.165
-
Maroni PD, Crawford ED. Surgical management of prostate cancer: optimizing patient selections and clinical outcome. Surg Oncol Clin N Am. 2005 Apr; 14(2):301-19.
Score: 0.155
-
Moses KA, Sprenkle PC, Bahler C, Box G, Carlsson SV, Catalona WJ, Dahl DM, Dall'Era M, Davis JW, Drake BF, Epstein JI, Etzioni RB, Farrington TA, Garraway IP, Jarrard D, Kauffman E, Kaye D, Kibel AS, LaGrange CA, Maroni P, Ponsky L, Reys B, Salami SS, Sanchez A, Seibert TM, Shaneyfelt TM, Smaldone MC, Sonn G, Tyson MD, Vapiwala N, Wake R, Washington S, Yu A, Yuh B, Berardi RA, Freedman-Cass DA. NCCN Guidelines? Insights: Prostate Cancer Early Detection, Version 1.2023. J Natl Compr Canc Netw. 2023 03; 21(3):236-246.
Score: 0.134
-
Raina K, Kant R, Prasad RR, Kandhari K, Tomar M, Mishra N, Kumar R, Fox JT, Sei S, Shoemaker RH, Chen Y, Maroni P, Agarwal C, Agarwal R. Characterization of stage-specific tumor progression in TMPRSS2-ERG (fusion)-driven and non-fusion-driven prostate cancer in GEM models. Mol Carcinog. 2022 07; 61(7):717-734.
Score: 0.127
-
Prasad RR, Raina K, Mishra N, Tomar MS, Kumar R, Palmer AE, Maroni P, Agarwal R. Stage-specific differential expression of zinc transporter SLC30A and SLC39A family proteins during prostate tumorigenesis. Mol Carcinog. 2022 05; 61(5):454-471.
Score: 0.124
-
Sheridan A, Maroni P, Patel NU. Tips to start an MR-US fusion biopsy program. Abdom Radiol (NY). 2020 12; 45(12):4023-4027.
Score: 0.111
-
Stanton WN, Crawford ED, Arangua PB, La Rosa FG, van Bokhoven A, Lucia MS, Poage WL, Partin A, Maroni P, Werahera PN. Assessment of high-grade prostate cancer risk using prostate cancer biomarkers. Can J Urol. 2020 02; 27(1):10080-10085.
Score: 0.108
-
Gore JL, du Plessis M, Zhang J, Dai D, Thompson DJS, Karsh L, Lane B, Franks M, Chen DYT, Bianco FJ, Brown G, Clark W, Kibel AS, Kim H, Lowrance W, Manoharan M, Maroni P, Perrapato S, Sieber P, Trabulsi EJ, Waterhouse R, Spratt DE, Davicioni E, Lotan Y, Lin DW. Clinical Utility of a Genomic Classifier in Men Undergoing Radical Prostatectomy: The PRO-IMPACT Trial. Pract Radiat Oncol. 2020 Mar - Apr; 10(2):e82-e90.
Score: 0.107
-
Bidikov L, Maroni P, Kim S, Crawford ED. 67-year-old Male with Prostatic Stromal Tumor of Uncertain Malignant Potential. Oncology (Williston Park). 2019 Sep 20; 33(9).
Score: 0.106
-
Crawford ED, Koo PJ, Shore N, Slovin SF, Concepcion RS, Freedland SJ, Gomella LG, Karsh L, Keane TE, Maroni P, Penson D, Petrylak DP, Ross A, Mouraviev V, Reiter RE, Divgi C, Yu EY. A Clinician's Guide to Next Generation Imaging in Patients With Advanced Prostate Cancer (RADAR III). J Urol. 2019 04; 201(4):682-692.
Score: 0.102
-
Tyagi A, Kumar S, Raina K, Wempe MF, Maroni PD, Agarwal R, Agarwal C. Differential effect of grape seed extract and its active constituent procyanidin B2 3,3?-di-O-gallate against prostate cancer stem cells. Mol Carcinog. 2019 07; 58(7):1105-1117.
Score: 0.102
-
Gershman B, Maroni P, Tilburt JC, Volk RJ, Konety B, Bennett CL, Kutikov A, Smaldone MC, Chen V, Kim SP. A national survey of radiation oncologists and urologists on prediction tools and nomograms for localized prostate cancer. World J Urol. 2019 Oct; 37(10):2099-2108.
Score: 0.101
-
Kessler ER, Su LJ, Gao D, Torkko KC, Wacker M, Anduha M, Chronister N, Maroni P, Crawford ED, Flaig TW, Glode LM, Lam ET. Phase II Trial of Acai Juice Product in Biochemically Recurrent Prostate Cancer. Integr Cancer Ther. 2018 12; 17(4):1103-1108.
Score: 0.099
-
Robin TP, Maroni PD, Chin BB, La Rosa FG, Bernard B, Pugh TJ. Post-Prostatectomy Radiation Therapy: Patient Selection, Timing, Imaging, and Therapy Intensification. Oncology (Williston Park). 2018 07 15; 32(7):360-3, 369, CV3.
Score: 0.097
-
Maccini MA, Westfall NJ, Van Bokhoven A, Lucia MS, Poage W, Maroni PD, Wilson SS, Glod? LM, Arangua P, Newmark J, Steiner M, Werahera PN, Crawford ED. The effect of digital rectal exam on the 4Kscore for aggressive prostate cancer. Prostate. 2018 05; 78(7):506-511.
Score: 0.095
-
Gore JL, du Plessis M, Santiago-Jim?nez M, Yousefi K, Thompson DJS, Karsh L, Lane BR, Franks M, Chen DYT, Bandyk M, Bianco FJ, Brown G, Clark W, Kibel AS, Kim HL, Lowrance W, Manoharan M, Maroni P, Perrapato S, Sieber P, Trabulsi EJ, Waterhouse R, Davicioni E, Lotan Y, Lin DW. Decipher test impacts decision making among patients considering adjuvant and salvage treatment after radical prostatectomy: Interim results from the Multicenter Prospective PRO-IMPACT study. Cancer. 2017 Aug 01; 123(15):2850-2859.
Score: 0.089
-
Amini A, Raben D, Crawford ED, Flaig TW, Kessler ER, Lam ET, Maroni P, Pugh TJ. Patient characterization and usage trends of proton beam therapy for localized prostate cancer in the United States: A study of the National Cancer Database. Urol Oncol. 2017 06; 35(6):438-446.
Score: 0.088
-
Werahera PN, Jasion EA, Crawford ED, Lucia MS, van Bokhoven A, Sullivan HT, Kim FJ, Maroni PD, Port JD, Daily JW, La Rosa FG. Diffuse reflectance spectroscopy can differentiate high grade and low grade prostatic carcinoma. Annu Int Conf IEEE Eng Med Biol Soc. 2016 Aug; 2016:5148-5151.
Score: 0.085
-
Carroll PR, Parsons JK, Andriole G, Bahnson RR, Castle EP, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB, Farrington T, Hemstreet GP, Kawachi MH, Kim S, Lange PH, Loughlin KR, Lowrance W, Maroni P, Mohler J, Morgan TM, Moses KA, Nadler RB, Poch M, Scales C, Shaneyfelt TM, Smaldone MC, Sonn G, Sprenkle P, Vickers AJ, Wake R, Shead DA, Freedman-Cass DA. NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016. J Natl Compr Canc Netw. 2016 May; 14(5):509-19.
Score: 0.084
-
Amini A, Jones BL, Jackson MW, Rusthoven CG, Maroni P, Kavanagh BD, Raben D. Survival outcomes of combined external beam radiotherapy and brachytherapy vs. brachytherapy alone for intermediate-risk prostate cancer patients using the National Cancer Data Base. Brachytherapy. 2016 Mar-Apr; 15(2):136-46.
Score: 0.082
-
Carroll PR, Parsons JK, Andriole G, Bahnson RR, Barocas DA, Castle EP, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB, Farrington T, Hemstreet GP, Kawachi MH, Lange PH, Loughlin KR, Lowrance W, Maroni P, Mohler J, Morgan TM, Nadler RB, Poch M, Scales C, Shaneyfelt TM, Smaldone MC, Sonn G, Sprenke P, Vickers AJ, Wake R, Shead DA, Freedman-Cass D. NCCN Clinical Practice Guidelines Prostate Cancer Early Detection, Version 2.2015. J Natl Compr Canc Netw. 2015 Dec; 13(12):1534-61.
Score: 0.081
-
Amini A, Jones B, Jackson MW, Yeh N, Waxweiler TV, Maroni P, Kavanagh BD, Raben D. Survival Outcomes of Dose-Escalated External Beam Radiotherapy versus Combined Brachytherapy for Intermediate and High Risk Prostate Cancer Using the National Cancer Data Base. J Urol. 2016 May; 195(5):1453-1458.
Score: 0.081
-
Schlaepfer IR, Nambiar DK, Ramteke A, Kumar R, Dhar D, Agarwal C, Bergman B, Graner M, Maroni P, Singh RP, Agarwal R, Deep G. Hypoxia induces triglycerides accumulation in prostate cancer cells and extracellular vesicles supporting growth and invasiveness following reoxygenation. Oncotarget. 2015 Sep 08; 6(26):22836-56.
Score: 0.080
-
Schlaepfer IR, Glod? LM, Hitz CA, Pac CT, Boyle KE, Maroni P, Deep G, Agarwal R, Lucia SM, Cramer SD, Serkova NJ, Eckel RH. Inhibition of Lipid Oxidation Increases Glucose Metabolism and Enhances 2-Deoxy-2-[(18)F]Fluoro-D-Glucose Uptake in Prostate Cancer Mouse Xenografts. Mol Imaging Biol. 2015 Aug; 17(4):529-38.
Score: 0.079
-
Carroll PR, Parsons JK, Andriole G, Bahnson RR, Barocas DA, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB, Giri VN, Hemstreet GP, Kawachi MH, Lange PH, Loughlin KR, Lowrance W, Maroni P, Mohler J, Morgan TM, Nadler RB, Poch M, Scales C, Shanefelt TM, Vickers AJ, Wake R, Shead DA, Ho M. Prostate cancer early detection, version 1.2014. Featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2014 Sep; 12(9):1211-9; quiz 1219.
Score: 0.075
-
Rusthoven CG, Carlson JA, Waxweiler TV, Raben D, Dewitt PE, Crawford ED, Maroni PD, Kavanagh BD. The impact of definitive local therapy for lymph node-positive prostate cancer: a population-based study. Int J Radiat Oncol Biol Phys. 2014 Apr 01; 88(5):1064-73.
Score: 0.072
-
Werahera PN, Jasion EA, Crawford ED, La Rosa FG, Lucia MS, van Bokhoven A, Sullivan HT, Port JD, Maroni PD, Daily JW. Systematic diagnosis of prostate cancer using an optical biopsy needle adjunct with fluorescence spectroscopy. Annu Int Conf IEEE Eng Med Biol Soc. 2014; 2014:2165-8.
Score: 0.071
-
Crawford ED, Rove KO, Barqawi AB, Maroni PD, Werahera PN, Baer CA, Koul HK, Rove CA, Lucia MS, La Rosa FG. Clinical-pathologic correlation between transperineal mapping biopsies of the prostate and three-dimensional reconstruction of prostatectomy specimens. Prostate. 2013 May; 73(7):778-87.
Score: 0.066
-
Koul HK, Kumar B, Koul S, Deb AA, Hwa JS, Maroni P, van Bokhoven A, Lucia MS, Kim FJ, Meacham RB. The role of inflammation and infection in prostate cancer: Importance in prevention, diagnosis and treatment. Drugs Today (Barc). 2010 Dec; 46(12):929-43.
Score: 0.057
-
Johnson TR, Koul S, Kumar B, Khandrika L, Venezia S, Maroni PD, Meacham RB, Koul HK. Loss of PDEF, a prostate-derived Ets factor is associated with aggressive phenotype of prostate cancer: regulation of MMP 9 by PDEF. Mol Cancer. 2010 Jun 15; 9:148.
Score: 0.056
-
Khandrika L, Kumar B, Koul S, Maroni P, Koul HK. Oxidative stress in prostate cancer. Cancer Lett. 2009 Sep 18; 282(2):125-36.
Score: 0.051
-
Khandrika L, Lieberman R, Koul S, Kumar B, Maroni P, Chandhoke R, Meacham RB, Koul HK. Hypoxia-associated p38 mitogen-activated protein kinase-mediated androgen receptor activation and increased HIF-1alpha levels contribute to emergence of an aggressive phenotype in prostate cancer. Oncogene. 2009 Mar 05; 28(9):1248-60.
Score: 0.050
-
Johnson TR, Khandrika L, Kumar B, Venezia S, Koul S, Chandhoke R, Maroni P, Donohue R, Meacham RB, Koul HK. Focal adhesion kinase controls aggressive phenotype of androgen-independent prostate cancer. Mol Cancer Res. 2008 Oct; 6(10):1639-48.
Score: 0.049
-
Koul HK, Maroni PD, Meacham RB, Crawford D, Koul S. p42/p44 Mitogen-activated protein kinase signal transduction pathway: a novel target for the treatment of hormone-resistant prostate cancer? Ann N Y Acad Sci. 2004 Dec; 1030:243-52.
Score: 0.038
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|